Mirae Asset Global Investments Co. Ltd. Purchases New Stake in Sanofi $SNY

Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Sanofi (NASDAQ:SNY) during the 3rd quarter, Holdings Channel.com reports. The firm acquired 18,987 shares of the company’s stock, valued at approximately $783,000.

Several other large investors have also recently added to or reduced their stakes in the company. Allworth Financial LP increased its stake in Sanofi by 2.7% during the second quarter. Allworth Financial LP now owns 9,233 shares of the company’s stock valued at $394,000 after purchasing an additional 243 shares during the last quarter. Focused Alpha LLC raised its holdings in shares of Sanofi by 4.5% during the third quarter. Focused Alpha LLC now owns 6,553 shares of the company’s stock worth $270,000 after purchasing an additional 281 shares during the period. Intrua Financial LLC lifted its position in shares of Sanofi by 6.4% in the 3rd quarter. Intrua Financial LLC now owns 5,100 shares of the company’s stock worth $210,000 after buying an additional 309 shares during the last quarter. Arkadios Wealth Advisors lifted its position in shares of Sanofi by 0.9% in the 1st quarter. Arkadios Wealth Advisors now owns 36,146 shares of the company’s stock worth $1,742,000 after buying an additional 315 shares during the last quarter. Finally, Avior Wealth Management LLC lifted its position in shares of Sanofi by 5.2% in the 3rd quarter. Avior Wealth Management LLC now owns 6,412 shares of the company’s stock worth $264,000 after buying an additional 319 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors.

Sanofi Price Performance

Shares of SNY opened at $47.04 on Monday. Sanofi has a 12 month low of $39.07 and a 12 month high of $52.68. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.12 and a quick ratio of 0.27. The stock has a fifty day moving average price of $42.30 and a 200 day moving average price of $44.34. The company has a market cap of $114.04 billion, a P/E ratio of 23.29, a PEG ratio of 1.29 and a beta of 0.31.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 30th. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.56 by $0.48. Sanofi had a return on equity of 15.16% and a net margin of 8.70%. The company had revenue of $17.25 billion for the quarter, compared to analysts’ expectations of $14.30 billion. During the same period last year, the business posted $2.91 earnings per share. The firm’s quarterly revenue was up 16.2% compared to the same quarter last year. On average, research analysts forecast that Sanofi will post 5.06 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on SNY. HSBC reaffirmed a “buy” rating on shares of Sanofi in a report on Thursday, September 10th. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research note on Thursday, October 1st. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a report on Saturday. Royal Bank Of Canada started coverage on Sanofi in a research note on Tuesday, September 8th. They issued a “sector perform” rating for the company. Finally, DZ Bank reaffirmed a “buy” rating on shares of Sanofi in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and thirteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $49.50.

About Sanofi

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world.

Sanofi traces its origins to a company established in France in 1973.